Equation 1 (Levetiracetam Injection 1)
Levetiracetam Injection, Solution, Concentrate
Product Images NDC 39822-4000
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 39822-4000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Xgen Pharmaceuticals Djb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fig 6 (Levetiracetam Injection 10)
The text shows the percentage of patients for two groups of medication, Placebo, and Levetiracetam, with sample sizes of 84 and 79, respectively. The numbers range from 0% to 80%, indicating the effectiveness of medication. The asterisk at the end of the Levetiracetam row suggests that it was found to be statistically more significant than the placebo.*
June 2020 (Levetiracetam Injection 11)
This is a label or description of a pharmaceutical product called Levetiracetam Injection. It has to be diluted before use and can only be used for intravenous administration. The other text seems to be irrelevant and might be errors.*
June 2020 (Levetiracetam Injection 12)
This is a description of a medication called Levetiracetam Injection, produced by Mylan Laboratories Limited in Bangalore, India, and distributed by X-Gen Pharmaceuticals, Inc. The medication comes in a box containing 10 single-dose 5 mL vials, each of which must be diluted before intravenous administration. Each vial contains 500 mg of levetiracetam, along with sodium acetate trihydrate, sodium chloride, and glacial acetic acid. The medication should be stored at room temperature, between 20° and 25°C (68°-77°F), and unused portions should be discarded. Detailed dosage guidance is included in the package insert.*
Equation 2 (Levetiracetam Injection 2)
This is a medical formula used to estimate the renal clearance or glomerular filtration rate (GFR) of a patient. The first part of the equation calculates an estimated average GFR based on the patient's age and weight. The second part of the equation uses the patient's serum creatinine level to adjust the estimated GFR. The formula includes a correction factor for female patients by multiplying the serum creatinine value by 0.85.*
Equation 3 (Levetiracetam Injection 3)
This appears to be a medical or scientific notation for measuring renal clearance rate and body surface area of a subject. The first line shows a value for "Cler" in units of "mU/min/1.73m²" which may refer to renal plasma clearance rate per unit of body surface area. The second line converts this value to "mL/min" which may be a more commonly used unit for renal clearance rate. The third line shows a value for "BSA subject" in units of "m²" which could refer to the body surface area of the subject being measured.*
Molecular Formula (Levetiracetam Injection 4)
Fig 1 (Levetiracetam Injection 5)
This appears to be a table or graph showing the percentage of patients in a study who received a placebo or different doses of levetiracetam, an anti-seizure medication. The numbers in parentheses indicate the sample size for each group. The asterisk suggests that the 1000 mg/day dose of levetiracetam had a statistically significant effect compared to placebo.*
Fig 2 (Levetiracetam Injection 6)
This text appears to be part of a table displaying the percentage of patients in a clinical trial who were given either a placebo or different doses of a drug named Loviracetam or Leveliracetam. There are three columns indicating the type of treatment and the number of patients in each group. The asterisk (*) mark indicates statistically significant differences versus the placebo group. Further information about the clinical trial is not available from this text.*
Fig 3 (Levetiracetam Injection 7)
The text represents the percentage of patients in a study, divided into five categories: 0%, 10%, 20%, 30%, and 40%. The study evaluated the effectiveness of Levetiracetam 3000 mg/day compared to a placebo. There were 104 patients in the placebo group and 180 in the Levetiracetam group. The asterisk at the bottom indicates that the Levetiracetam group had statistically significant results compared to the placebo group.*
Fig 4 (Levetiracetam Injection 8)
The text is a table showing the percentage of patients who received either placebo or levetiracetam. There is a note that some of the data was statistically significant compared to placebo. No specific information is given about what the data represents.*
Fig 5 (Levetiracetam Injection 9)
The text describes the percentage of patients who responded to either placebo or evetiracetam. 50% of patients who were administered with evetiracetam showed a response rate of 43.1% which was statistically significant than the placebo group consisting of 51 individuals. The remaining text signifies the percentages of the response rates of the 2 groups which were observed.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
